Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. - Wikidata - awgldk - TriplyDB

Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice.

Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice.

http://www.wikidata.org/entity/Q43263819

about

Vaccine against arteriosclerosis: an update.CD8+ T cell activation predominate early immune responses to hypercholesterolemia in Apoe⁻(/)⁻ mice.Immunization with advanced glycation end products modified low density lipoprotein inhibits atherosclerosis progression in diabetic apoE and LDLR null mice The autoimmune concept of atherosclerosis.CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice Modulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J mice Vaccination to modulate atherosclerosis Beyond vascular inflammation--recent advances in understanding atherosclerosis.Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development Ablation of CD8α(+) dendritic cell mediated cross-presentation does not impact atherosclerosis in hyperlipidemic mice.Vaccination against T-cell epitopes of native ApoB100 reduces vascular inflammation and disease in a humanized mouse model of atherosclerosis.microRNA-181a represses ox-LDL-stimulated inflammatory response in dendritic cell by targeting c-Fos.MicroRNA-155 induces differentiation of RAW264.7 cells into dendritic-like cells.Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs.Resveratrol protects against diet-induced atherosclerosis by reducing low-density lipoprotein cholesterol and inhibiting inflammation in apolipoprotein E-deficient mice.Effect of dietary cholesterol and cholesterol oxides on blood cholesterol, lipids, and the development of atherosclerosis in rabbits.The role of the vascular dendritic cell network in atherosclerosis.Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis.Dendritic cells in atherosclerosis.Advances in immune-modulating therapies to treat atherosclerotic cardiovascular diseases oxLDL antibody inhibits MCP-1 release in monocytes/macrophages by regulating Ca2+ /K+ channel flow Dendritic cells and their role in atherogenesis.Current advances in understanding of immunopathology of atherosclerosis.Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets.Dendritic cells and regulatory T cells in atherosclerosis.Inflammation and immune system interactions in atherosclerosis.Molecular biology of atherosclerosis.Dendritic cells in atherosclerotic inflammation: the complexity of functions and the peculiarities of pathophysiological effects Regulatory T cells in atherosclerosis: critical immune regulatory function and therapeutic potential.Prospects for the therapeutic application of sulfated polysaccharides of brown algae in diseases of the cardiovascular system: review.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Dendritic Cell KLF2 Expression Regulates T Cell Activation and Proatherogenic Immune Responses.The immunology of atherosclerosis.Deletion of Batf3-dependent antigen-presenting cells does not affect atherosclerotic lesion formation in mice.Oxidized Low-Density Lipoprotein Loading of Macrophages Downregulates TLR-Induced Proinflammatory Responses in a Gene-Specific and Temporal Manner through Transcriptional Control.Newer antiatherosclerosis treatment strategies.Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development.Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice.Anti-inflammatory Nanomedicine for Cardiovascular Disease.New Alternatives for Atherosclerosis Treatment Based on Immunomodulation

P2860

Q33641227-536B35E4-7A68-40F0-A5A2-19BF27BD5E07 Q33761718-7FF80D1E-42D3-40DD-9DB0-CD87D9218554 Q34528035-6DC478B8-8143-4743-911B-2470979E0F8C Q35550211-20DCD253-972B-4265-AFB5-5F0509B92E97 Q35572404-BD2856D8-E1E2-4619-95FB-72756BA21CB8 Q35591762-CF3E9B2E-F5DA-4494-918B-DF372AA64F04 Q35600876-E9AC16EA-48F1-4615-B8C8-37F7F1C045EF Q36079808-8B4B4090-36F6-4F90-AAEF-1766A4018553 Q36141999-8F162410-FB90-4D86-9799-5E9CFD15B3B6 Q36186394-34B4212E-7304-4B3A-99E8-6F12A5914020 Q36279562-BC493389-CF65-41A3-9A8C-FA4D609E7035 Q36302743-39C5896F-24C2-4EFB-A0E1-22E318FC7C16 Q36464336-A174DD46-70CB-4EC3-B08F-88617E887EC9 Q36497238-7B5C3D99-387E-40CC-B930-D1AE38334686 Q36608631-3C02A244-A144-4404-A408-0AE19953E5A4 Q37007386-3A334DD5-A40A-4BD4-98CB-131A78CD841B Q37050929-B473001C-9B98-4391-B755-35867559E9EA Q37407750-5042D9E7-A961-4258-AE90-88650F8DB241 Q37624571-B39534FB-013F-4B90-A8D3-113D01F093EF Q37709623-4009D855-C5FD-401E-A09C-593F0A746B92 Q37747331-18CCC8B1-2A44-43F9-BCA2-399C7B15493C Q37748449-4B03790F-BBC9-460F-AD9D-034BF54F4CC4 Q37808645-4429CCEA-894E-4E3C-BC3A-EC748B883CAE Q37866627-78D7CE8C-197D-4BF6-91BD-3A4C6E30E808 Q38023274-4A57239F-88FD-4551-B195-B80319CA82A5 Q38083555-47856CD2-B57B-4750-B8F6-58FA81373304 Q38125279-AA6644E2-92D5-46EA-892C-49166F3FD918 Q38218096-5AFCC91C-890A-435D-8235-B4723167E960 Q38620803-1465A872-5672-4AB3-9764-C00A5C553073 Q38850914-5F573AF2-B997-4759-98A4-1CB9A99BEEB2 Q38851472-5BBCDE49-2F53-4349-9C86-D53297F919F9 Q39193752-B2DD1434-8979-4896-A935-97B02E844F6B Q39230390-5FA9B610-CBD5-4127-ABAB-693864594FF9 Q41235781-922B90C3-4D09-4629-B387-985EE56A2C26 Q42513358-8D5E7633-3285-4F73-94B4-F8207317B724 Q42737139-2EEA111D-D7A1-4361-9BE8-AC245770B6D7 Q42832475-6D1F55FF-3E49-487E-8DB8-061AA2309345 Q43089504-C7F098F8-B3DE-4D52-BBAD-DDD5B3864198 Q47744781-F8A5D671-8DE0-4BDB-9983-E18015ABED36 Q58692371-7B9ED1EB-99F0-47AD-9326-89F65D45003C

P2860

Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice.

http://www.wikidata.org/entity/Q43263819

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@en

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@nl

type

label

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@en

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@nl

prefLabel

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@en

Vaccination using oxidized low ...... n LDL receptor-deficient mice.

@nl

P1433

Q43263819-28BE65D1-C788-4886-A680-4C5600022D2D

P1476

Q43263819-82C979F6-44C3-4AA7-ADAC-D65B63750F64

P2093

Q43263819-16BF3D5C-B76B-46BA-A14C-C7ADBE4529BF

Q43263819-25DFDD39-85FB-407F-8811-4F7EAFFBED0F

Q43263819-3921900C-F3CC-44BD-9F59-8CAFD4C30A5A

Q43263819-6462FFFB-AC44-433D-B5C1-5B9AAC1EA8C3

Q43263819-796B76F0-2947-4EBC-B9D5-B8116F8EE60C

Q43263819-79A4585F-2550-4B56-B2F7-5A85E165E799

Q43263819-8EA51BFF-4091-4965-A9C1-4A3379C1BCCD

Q43263819-FA2D7222-8AC0-4713-B8F5-B39408765BDD

P2860

Q43263819-0AF29044-C952-4B41-B427-D6ABBE83A00C

Q43263819-0B2EC824-B171-4524-998A-7AE1329C9F60

Q43263819-15FFCB52-3B19-4629-AA0C-9E045743D691

Q43263819-26761F17-4BCA-4366-82D6-6E98537ED1D5

Q43263819-2AC7266C-E2A6-48D4-BD09-6B933C80793F

Q43263819-33DC6636-A8FF-4E89-A04D-D27508195288

Q43263819-44FB4ADE-B462-4EE3-895B-3EA33D405E12

Q43263819-4A71250B-08F6-4A48-B7D1-D97987185304

Q43263819-53B3E0D8-A652-4CD3-8924-42D8C1B8E507

Q43263819-5B1D43DA-F0D1-41A4-B772-B30AF5801B8D

P304

Q43263819-511D0A63-0A7A-4007-AC38-51E65F4014F8

P31

Q43263819-D13A4C3C-5FF4-4ED4-AB27-224DC7F0312A

P356

Q43263819-38D65E64-5585-446C-A69B-FCA684831894

P433

Q43263819-3025ACB3-A560-4239-A318-8ABFF42F5709

P478

Q43263819-13F1AE07-68E0-41AC-A968-290E17CE671A

P50

Q43263819-D87691C3-BC59-4EB5-9ECA-6BBE6E95BF9A

P577

Q43263819-B15259DC-B866-4789-98FE-B3BF464F9364

P698

Q43263819-A4F008DD-C432-4D59-AC02-E09F1AB19D0A

P921

Q43263819-0B81F1B3-1F77-4358-83B0-117B2CD9CD84

Q43263819-689E558C-AD67-49B2-97D6-6C656790632C

P356

P1433

Cardiovascular Research

P1476

Vaccination using oxidized low ...... in LDL receptor-deficient mice

@en

P2093

Eva J A van Wanrooij

http://www.w3.org/2001/XMLSchema#string

Gijs H M van Puijvelde

http://www.w3.org/2001/XMLSchema#string

Jan-Willem Cohen Tervaert

http://www.w3.org/2001/XMLSchema#string

Johan Kuiper

http://www.w3.org/2001/XMLSchema#string

Kim L L Habets

http://www.w3.org/2001/XMLSchema#string

Leonie M van Duivenvoorde

http://www.w3.org/2001/XMLSchema#string

Paula de Vos

http://www.w3.org/2001/XMLSchema#string

Theo J C van Berkel

http://www.w3.org/2001/XMLSchema#string

P2860

Atherosclerosis

Immunobiology of dendritic cells

Inflammation and atherosclerosis

Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo.

Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences.

LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis.

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.

Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression.

Immune mechanisms in atherosclerosis.

Separation of plasma lipoproteins by density-gradient ultracentrifugation.

P304

622-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CVR/CVP338

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19819882

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis